Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs

Molecular Cancer Therapeutics - Tập 4 Số 4 - Trang 659-667 - 2005
Christopher P. Landowski1, Balvinder S. Vig1, Xueqin Song1, Gordon L. Amidon1
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan

Tóm tắt

Abstract Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas and hepatic metastases. However, prodrug strategies may be necessary to improve its physiochemical properties and selectivity and to reduce undesirable toxicity effects. Previous studies with amino acid ester prodrugs of nucleoside drugs targeted to the PEPT1 transporter coupled with recent findings of the functional expression of the PEPT1 oligopeptide transporter in pancreatic adenocarcinoma cell lines suggest the potential of PEPT1 as therapeutic targets for cancer treatment. In this report, we show the feasibility of achieving enhanced transport and selective antiproliferative action of amino acid ester prodrugs of floxuridine in cell systems overexpressing PEPT1. All prodrugs exhibited affinity for PEPT1 (IC50, 1.1–2.3 mmol/L). However, only the prolyl and lysyl prodrugs exhibited enhanced uptake (2- to 8-fold) with HeLa/PEPT1 cells compared with HeLa cells, suggesting that the aspartyl prodrugs are PEPT1 inhibitors. The selective growth inhibition of Madine-Darby canine kidney (MDCK)/PEPT1 cells over MDCK cells by the prodrugs was consistent with the extent of their PEPT1-mediated transport. All ester prodrugs hydrolyzed to floxuridine fastest in Caco-2 cell and MDCK homogenates and slower in human plasma and were most chemically stable in pH 6.0 buffer. Prolyl and lysyl prodrugs were relatively less stable compared with aspartyl prodrugs in buffers and in cell homogenates. The results suggest that optimal design for targeted delivery would be possible by combining both stability and transport characteristics afforded by the promoiety.

Từ khóa


Tài liệu tham khảo

Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299–313.

Nishizawa Y, Casida JE. 3′,5′-Diesters of 5-fluoro-2′-deoxyuridine: synthesis and biological activity. Biochem Pharmacol 1965;14:1605–19.

Kawaguchi T, Saito M, Suzuki Y, Nambu N, Nagai T. Specificity of esterases and structure of prodrug esters. II. Hydrolytic regeneration behavior of 5-fluoro-2′ deoxyuridine (FUdR) from 3′,5′-diesters of FUdR with rat tissue homogenates and plasma in relation to their antitumor activity. Chem Pharm Bull (Tokyo) 1985;33:1652–9.

Tobias SC, Borch RF. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J Med Chem 2001;44:4475–80.

Wei Y, Yan Y, Pei D, Gong B. A photoactivated prodrug. Bioorg Med Chem Lett 1998;8:2419–22.

Vig BS, Lorenzi PJ, Mittal S, et al. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 2003;20:1381–8.

Shin HC, Landowski CP, Amidon GL. Transporters in the GI Tract. In: Van de Waterbeemd H, Lennernas H, Artursson P, editors. Drug bioavailability/estimation of solubility, permeability and absorption (Series: Methods and principles in medicinal chemistry). Weinheim (Germany): Wiley-VCH Verlag GmbH; 2003. p. 245–87.

Han H, de Vrueh RL, Rhie JK, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998a;15:1154–9.

Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000;89:781–9.

Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach FH. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 1998;246:470–5.

Gonzalez DE, Covitz KM, Sadee W, Mrsny RJ. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 1998;58:519–25.

Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819–26.

Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 1997;57:4118–22.

Nakanishi T, Tamai I, Takaki A, Tsuji A. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 2000;88:274–80.

Casida JE, Engel JL, Nishizawa Y. 3′,5′-Diesters of 5-fluoro-2′-deoxyuridine and thymidine: hydrolysis by esterases in human, mouse, and insect tissue. Biochem Pharmacol 1966;15:627–44.

Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet 1985;10:392–403.

Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos 2002;30:488–93.

Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 2003;278:25348–56.

Kim I, Song X, Vig BS, et al. A novel nucleoside prodrug activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 2004;1:117–27.

Landowski CP, Sun D, Foster DR, et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther 2003;306:778–86.

Hsu CP, Hilfinger JM, Walter E, Merkle HP, Roessler BJ, Amidon GL. Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res 1998;15:1376–81.

Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res 1998b;15:1382–6.

Bruice TC, Benkovic S. Bioorganic mechanisms. New York: W.A. Benjamin, Inc.; 1966.

Kawaguchi T, Fukushima S, Hayashi Y, Nakano M. Nonenzymatic and enzymatic hydrolysis of 5-fluoro-2′-deoxyuridine (FUdR) esters. Pharm Res 1988;5:741–4.

Beauchamp LM, Orr GF, de Miranda P, Burnette T, Kernitsy TA. Amino acid ester prodrugs of acyclovir. Antivir Chem Chemother 1992;3:157–64.

Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 1998;19:209–17.

Wahl ML, Owen JA, Burd R, et al. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002;1:617–28.

Schornack PA, Gillies RJ. Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia 2003;5:135–45.

Friedrichsen GM, Chen W, Begtrup M, Lee CP, Smith PL, Borchardt RT. Synthesis of analogs of l-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells. Eur J Pharm Sci 2002;16:1–13.

Amidon GL, Chang M, Fleisher D, Allen R. Intestinal absorption of amino acid derivatives: importance of the free α-amino group. J Pharm Sci 1982;71:1138–41.

Yang C, Gao H, Mitra AK. Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir. J Pharm Sci 2001;90:617–24.

Glenner GG, McMillan PJ, Folk JE. A mammalian peptidase specific for the hydrolysis of N-terminal α-l-glutamyl and aspartyl residues. Nature 1962;194:867.

Zhan CG, Zheng F, Landry DW. Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. J Am Chem Soc 2003;125:2462–74.

Faria TN, Timoszyk JK, Stouch TR, et al. A novel high-throughput pept1 transporter assay differentiates between substrates and antagonists. Mol Pharm 2004;1:67–76.

Thông tin
Thông tin xuất bản

Molecular Cancer Therapeutics

Tập 4 Số 4

659-667

Thông tin tác giả